- The NDA is based on two P-III studies and an interim analysis from an ongoing OLE study which includes assessing Zogenix in 232 patients with Dravet syndrome for up to 21mos.
- The two P-III study resulted in meeting 1EPs and all 2EPs. Additionally, Zogenix is also investigating Fintepla in Lennox-Gastaut syndrome in P-III study with its anticipated resulted in Q1’20
- Fintepla (ZX008, oral solution) is a therapy being developed for the treatment of seizures associated with Dravet syndrome with its PDUFA date as March 25, 2020
Click here to read full press release/ article | Ref: Zogenix | Image: LinkedIn